|
作用机制SARS-CoV-2 S protein抑制剂 |
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
|
原研机构- |
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase I Trial of an Immunotherapy (HCVax™) in Chronic Hepatitis C Infected Patients
GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax™) in chronic HCV patients.
A Phase I Trial of a Therapeutic Vaccine (Covax-19™) in SARS-CoV-2 Infected Patients
GC004 is a Phase I trial to evaluate the safety and the immune responses of a therapeutic vaccine in SARS-CoV-2 infected patients. Covid-19 confirmed patients with mild or no symptoms will be enrolled sequentially into low dose and high dose groups. Following the vaccination subjects who received at least one vaccination will be followed for safety through week 26.
A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX™) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy
This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The safety and immune responses will be studied in vaccine recipients. The anti-viral effect of HIVAX vaccine will be monitored during a 12-week treatment interruption phase.
100 项与 Genecure Biotechnologies 相关的临床结果
0 项与 Genecure Biotechnologies 相关的专利(医药)
100 项与 Genecure Biotechnologies 相关的药物交易
100 项与 Genecure Biotechnologies 相关的转化医学